• 参会报名
  • 会议介绍
  • 会议日程
  • 会议嘉宾
  • 参会指南
  • 邀请函下载

首页 > 商务会议 > 医疗医学会议 > CAR-TCR细胞与AAV基因治疗研发及创新峰会暨精准肿瘤免疫治疗研发领袖峰会2020 ( APRDL 2020 ) 更新时间:2020-08-21T11:15:41

CAR-TCR细胞与AAV基因治疗研发及创新峰会暨精准肿瘤免疫治疗研发领袖峰会2020 ( APRDL 2020 )
收藏人
分享到

CAR-TCR细胞与AAV基因治疗研发及创新峰会暨精准肿瘤免疫治疗研发领袖峰会2020 ( APRDL 2020 )

会议时间:2020-10-14 09:00至 2020-10-16 17:00结束

会议地点: 上海  上海浦东汤臣洲际大酒店  上海市浦东新区张扬路777号(近崂山东路)

会议规模:1000人

主办单位: 迪易咨询 Deliver Life Sciences 大费城美中医药协会(SAPA-GP) 百华协会 (BayHelix)

发票类型:增值税普通发票 增值税专用发票

门票名称单价截止时间数量
药企(Pharma/Biotech) 团体票买三赠一 ¥4800.0 2020-10-13 17:00
非药企(Service / Solution Providers) 团体票买三赠一 ¥6800.0 2020-10-13 17:00

会议介绍

会议内容 主办方介绍


CAR-TCR细胞与AAV基因治疗研发及创新峰会暨精准肿瘤免疫治疗研发领袖峰会2020 ( APRDL 2020 )

CAR-TCR细胞与AAV基因治疗研发及创新峰会暨精准肿瘤免疫治疗研发领袖峰会2020 ( APRDL 2020 ) 宣传图

定于10月14-16日上海浦东汤臣洲际大酒店Deliver Life Sciences 主办、大费城美中医药协会(SAPA-GP)和百华协会 (BayHelix) 共同支持的 CAR-TCR细胞与基因治疗研发及生产工艺技术论坛 暨 精准肿瘤免疫治疗研发领袖峰会2020,邀请了500+政府监管机构、行业协会、科研院校、临床研究中心、大型跨国制药公司、创新型生物技术公司、CAR-T, TCR-T, CAR-NK, TIL, AAV-based Gene Therapy 细胞及基因治疗免疫疗法研发企业、新药研发设备平台、细胞和基因治疗服务公司、医药研发服务公司、临床试验研究机构、人工智能以及解决方案提供商、律所、投资以及咨询机构等药物研发领袖及高层代表共同探讨并促进 :

-- CAR-TCR T细胞疗法及相关联合疗法在血液肿瘤和实体瘤临床研究的最新进展
-- 从技术开发的角度谈罕见病AAV基因治疗产品的开发现状


-- 开发新型细胞疗法产品治疗新冠肺炎COVID-19
-- 基于TCR免疫疗法治疗癌症和病毒感染
-- 开发安全且有效的CD-19 CAR-T 细胞治疗产品用以精准治疗血液肿瘤
-- 创新CD-7 CAR-T 细胞疗法治疗T细胞恶性肿瘤
-- CD30 CAR-T治疗霍奇金淋巴瘤的最新进展
-- 开发BCMA-CAR T细胞治疗复发/难治多发性骨髓瘤的最新进展
-- 下一代靶向 NKG2D CAR-T  细胞疗法的临床开发策略及研究进展
-- CAR-T细胞治疗实体瘤的研发策略, 挑战及解决方法
-- T细胞与肿瘤免疫治疗的最新研发进展
-- 双靶点CAR-T(CD19+CD22)治疗B急性淋巴瘤的最新研究进展
-- 新型NK免疫细胞治疗在实体瘤的临床研究机理及进展
-- 基于非病毒载体的CAR-T细胞肿瘤治疗

-- CAR-T细胞的动物研究模型与临床前研究
-- 精准TCR-T细胞受体疗法治疗实体瘤的机遇和挑战

-- 细胞与基因治疗产品的工业化与商业化开发
-- CAR T 生产工艺与建立中控及放行方法的考量
-- 细胞治疗与基因治疗工艺开发、工艺稳定性研究及工艺放大
-- 细胞治疗产品的商业化生产 策略与挑战

-- 细胞治疗产品的生产工艺与质量控制
-- 流式细胞术与CAR-T细胞研究
-- 基因编辑技术 ( CRISPR-Cas9 )与 iPSC 技术在细胞治疗产品研发与生产中的运用

--
开发和商业化全球创新药物的中国策略
-- 肿瘤免疫治疗药品开发及创新合作新模式
-- 抗肿瘤核酸干扰创新药(siRNA)治疗药物的开发
-- 未来精准癌症免疫疗法的革命性创新
-- 小分子药物用以治疗 合成性致死(Synthetic Lethality)癌症治疗


-- 开放式创新及研发外部合作模式, 药物研发外部合作及加速新药研发策略
-- 创新药物的开发策略及技术投资

-- 美中生物新药开发知识产权及专利策略
-- 企业并购与投资

同时为国内外专家高端交流,产业与资本对接搭建平台。

查看更多

迪易咨询 Deliver Life Sciences 迪易咨询 Deliver Life Sciences

Deliver Life Sciences is a specialty producer and organizer of the conference, workshop, public training together with the tailored consultative solutions to serve the growing biomedical industry in Asia. Through looking into the current trends of regulation, scientific findings and cutting-edge technology and working with the leading associations, regulatory agencies, industry and academia KOLs, we translate, formulate and promote our tailored offerings from the basic medicinal research, discovery to development till commercialization.

大费城美中医药协会(SAPA-GP)

百华协会 (BayHelix)

会议日程

(最终日程以会议现场为准)


更多详细英文日程及议题请联系客服索取

CAR-TCR细胞与基因治疗研发及创新峰会 议程和讨论热点:
主旨演讲:Engineering TCR-based Immunotherapy against Cancer and Viral Infection
-- Designing and applying TCR-T cell approaches for immunotherapy against viral infection
-- Developing a novel CAR, Synthetic TCR and Antigen Receptor (STAR), method for cancer immunotherapy

林欣 教授, 基础医学系系主任, 清华大学医学院 [ Dr. Xin Lin, Professor and Chairman, School of Medicine, Department of Basic Medical Sciences, Tsinghua University ]

主旨演讲:Developing AAV-based Gene Therapy Products in China, esp. from the Technical Development Front
肖溯 博士首席技术官武汉纽福斯生物科技有限公司 [ Dr. Su Xiao, Chief Technical Operation Officer, Neurophth Therapeutics ]

主旨演讲:Industrializing Cell & Gene Therapies: Managing Complexity Across the Ecosystem
刘必佐 先生, 首席执行官 首席财务官, 西比曼生物科技集团 [ Mr. Tony Liu, Chief Executive Officer & Chief Financial Officer, Cellular Biomedicine Group ]

主旨演讲:Revolution of CAR-T Cell Therapies: Regulatory and Commercialization Considerations for Yescarta & Tecartus in China
王立群 博士, 首席执行官, 复星凯特生物科技有限公司 [ Dr. Richard Wang, Chief Executive Officer, Fosun Kite Biotechnology ]

主旨演讲:CAR T Process Development and in Process and Batch Releasing Assay Development
-- Developing a dependable and consistent CAR T process for a qualified CAR T products
-- Developing the in process control and batch releasing assays to assure the quality of CAR T product

蒋忻坡 博士,  高级总监, 方法分析/工艺验证/QC/QA, 南京传奇生物 [ Dr. Xinpo Jiang, Senior Director, Analytical/Process Validation/QC/QA, Legend Biotech ]

 

主旨演讲:Translating and Developing Novel Cell Therapy Product for Fighting against COVID-19
-- Emerging Infectious Disease such as SARS, COVID-19 is one of the biggest human threat

-- The mechanism of action of cell therapy to treat COVID-19

-- The development of MSC product from bench to clinic during the pandemic

-- The outcome of clinical study of using MSCs to treat patients with severe COVID-19
张宇 博士, 高级副总裁兼首席科学官, 中源协和 [ Dr. Yu Zhang, Senior Vice President and Chief Scientific Officer, VCANBIO Cell & Gene Engineering ]

主旨演讲:Development of Safe and Potent CD19 CAR-T Cell Therapy in China targeting Hematological Malignancies
Abstract:
CD19-targeted chimeric antigen receptor-T (CAR-T) cells with CD28 or 4-1BB (28z CAR-T and BBz CAR-T) have shown great promise to treat relapsed or refractory (r/r) B cell non-Hodgkin’s lymphoma (B-NHL). However, parallel comparison of their clinical outcomes has never been reported. This study investigated their efficacy and adverse events in B-NHL therapy. Six patients with r/r B-NHL were initially enrolled and infused with 28z or BBz CAR-T cells at a dose of 0.75–5x105/kg. These CAR-T cells showed similar antitumor efficacies, with a complete response (CR) rate of 67% within 3 months. BBz CAR-T was well tolerated. However, severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in the 28z CAR-T cohort, resulting in the termination of further evaluation of 28z CAR-T. Three more patients were enrolled to investigate BBz CAR-T cells in-depth at an escalated dose (1-106/kg). All cases achieved CR within 3 months, and only grade 1/2 adverse events occurred. This study suggests that 4-1BB is more beneficial for the clinical performance of CAR-T cells than CD28 in CD19-targeted B-NHL therapy, at least under our manufacturing process.
何霆 博士, 首席执行官, 北京艺妙神州医药科技有限公司 [ Dr. Ting He, Chief Executive Officer, ImmunoChina Pharmaceuticals ]

主旨演讲:Novel CAR-T Therapy for T Cell Malignancies
Abstract: CD7 is an attractive therapeutic target for T-lymphoblastic leukemia/lymphoma (T-ALL/LBL). CD19-CAR-T for the treatment of R/R B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin's lymphoma (B-NHL) has achieved great success, and therefore greatly promoted the exploration of CAR-T cell therapy to other targets and indications, including T-ALL/T-LBL.However, some big challenges have to be overcome for CD7-CAR-T therapy, including 1) potential contamination by abnormal T cells in CAR-T products; 2) life-threatening T cell hypoplasia; and 3) CAR-T cell fratricide due to CD7 expression on normal T cells.A first-in-class autologous CD7-CAR-T cells were developed by PersonGen and exhibited exciting clinical efficacy and safety in treating R/R T-ALL/LBL.
- Clinical significance of T-ALL/LBL

- Challenges for CD7-CAR-T R&D

- Clinical progress of PersonGen’s CD7-CAR-T
杨林 博士, 首席执行官, 博生吉医药科技(苏州)有限公司 [ Dr. Lin Yang, Founder and Chairman, PersonGen BioTherapeutics ]

主旨演讲:Novel Proceeding about Targeting CD 30 CAR-T Therapy for Lymphoma
Abstract:
CAR-T cells therapy has been demonstrated good tolerability and effects in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphomas (ALCL). However, most studies utilized the second-generation CARs with either CD28 or 4-1BB costimulatory domains resulting in unsatisfactory complete remission rate. Here, we designed a novel third-generation CAR against CD30 and investigated the efficacy and safety on CD30 positive relapsed or refractory lymphoma patients.  We found that the anti-CD30 CAR-T cells specifically homing to the tumor with powerful anti-tumor activity in the tumor xenografts. We then conducted a pilot study to evaluate the safety and feasibility of anti-CD30 CAR-T cells which were infused simultaneously in 14 patients with r/r HL and ALCL.  The third-generation anti-CD30 CAR-T cells had superior expansion and longer persistence, and the lentiviral copies could be detected after CAR-T infusion for half a year.  Of Thirteen patients (92.9%) were successes responded and ten patients (71.4%) achieved complete remission (CR) for 12 months and also four patients remained in CR longer than two years in the patients (4/5) followed over two years. Our results showed that CRS occurred in eleven patients but was mild, only one patient developed CRS over 3 grade, and other 10 patients developed grade 1 or 2 CRS who did not require anti-IL6 therapy. Thus, anti-CD30 CAR-T cells is safety and effective for treating relapsed/ refractory HL and ALCL patients.
张同存 教授, 董事长, 武汉波睿达生物科技有限公司, 院长, 武汉科技大学生命科学与健康学院[ Dr. Tony Zhang, Chairman, Wuhan Bio-Raid Biotechnology ]

主旨演讲:Precision Immunotherapy: Development BCMA-Targeted CAR T-Cell Therapy for R/R Multiple Myeloma
-- Global status of BCMA-targeted CAR-T cells
-- Current situation of bispecific CAR-T cells targeting BCMA
-- Characteristics of CT103A, IASO Bio-therapeutics’ BCMA-targeted CAR-T cell product
-- Preliminary clinical data of CT103A

汪文 博士, 首席医学官, 驯鹿医药 [ Dr. Wen (Maxwell) Wang, Chief Medical Officer, IASO Biotherapeutics ]

主旨演讲:Solid Tumor CAR-T Barriers and Solutions
-- Solid tumor quite different from hematologic malignancies
-- Tumor microenvironment
-- CAR-T design, traditional CAR, novel concept CAR, TCR-like
-- Therapy combination

王恩秀 博士, 首席执行官, 南京卡提医学科技有限公司[ Dr. Enxiu Wang, Chief Executive Officer, Nanjing CART-MED ]

主旨演讲:Development of Next Generation Safe and Potent NKG2D CAR-T Cell Therapy and Next Generation CAR-T Cells
-- CAR-T development history
-- Safety and potent CART development background and cases show
-- Safety and potent KD-025 CAR-T Cell Therapy Progress
-- The case study of KAEDI next generation CAR-T Cells

代红久 博士, 首席执行官, 南京凯地生物科技有限公司 [ Dr. Hongjiu (Paul) Dai, Chief Executive Officer, Nanjing KAEDI Biotech ]

主旨演讲:The Latest Advancement in T-cell-based Cancer Immunotherapy
Abstract: Cancer is a leading cause of death worldwide. Traditional cancer treatments, including surgery, chemotherapy and radiation therapy, have demonstrated very limited efficacy for patients with late-stage disease. Cancer immunotherapy, particularly adoptive cell transfer, has shown great promise in the treatment of patients with late-stage disease, including those who are refractory to standard therapies. Chimeric antigen receptor (CAR)-T cells have achieved great success in treating hematological malignancies, while tumor infiltrating lymphocytes (TIL) and T cell receptor (TCR) -T cell-based immunotherapy have shown encouraging data for solid cancers. In this presentation, I will highlight the latest advancement in T-cell-based cancer immunotherapy based on TIL, TCR-T and CAR-T cells and discuss future directions and challenges in T cell-based cancer immunotherapy
王明军 教授, 执行院长, 深圳市因诺转化医学研究院 [ Dr. Mingjun Wang, Executive President, Shenzhen Institute for Innovation and Translational Medicine ]

主旨演讲:Mechanisms & Clinical Study of CAR-NK Cell Drugs to Treat Solid Tumours
Abstract: Chimeric antigen receptor T lymphocyte (CAR-T) technology has made remarkable success in the treatment of hematological malignancies. However, its intrinsic character of the technology unlikely leads to a large-scale production of standardized and homogenous cell drugs for cancer treatment. The ATCG Corp. has been pioneered on developing innovative “off-the-shelf” CAR-NK cell drugs for cancer immunotherapy. The ATCG research team, led by Dr. Huashun Li, has been based on natural killer cell line NK-92 as a platform to develop over 15 CAR stably expressing NK cell lines (CAR-NK) to treat different types of solid tumors. The preliminary clinical research studies have shown that ATCG427 CAR-NK therapy yields a remarkable response rate. In investigator initiated clinical study, Robo1 CAR-NK cells could effectively treat the advanced cancers with DCR as high as 76.5%, including but not limited to breast cancer, lung cancer, renal cancer, and pancreatic cancer. In addition, ATCG427 CAR-NK cells not only directly kill target tumor cells but also engage host NK cells and lymphocytes, leading to systemic activation of immunity against tumors. ATCG is a leading enterprise in the fast-growing tumor immunotherapy field .It has laid a solid foundation for the clinical trial of innovative cell drugs.
李华顺 博士, 总裁兼首席执行官, 阿思科力 [ Dr. Huashun Li, President and Chief Executive Officer, Asclepius Technology Company Group ]

主旨演讲:基于非病毒载体的CAR-T细胞肿瘤治疗 / Non-Viral CAR-T Cell Therapy for Tumor

-- 非病毒载体之于CAR-T肿瘤治疗的价值

-- 非病毒载体CAR-T药物研究

-- 非病毒载体CAR-T实体肿瘤治疗探索
孙艳 女士, 副总裁, 细胞药物BU总经理, 上海细胞治疗集团 [ Dr. Sun Yan, Vice President, General Manager, Cell Drug Business Unit, Shanghai Cell Therapy Group ]

主旨演讲:Precision TCR Redirected T Cell Immunity Treating Solid Tumour
-- The Evolution of TCR-T
-- XLifeSc 3rd Generation TCR-T
-- Case Studies of TCR-T Drug Treatment for Solid Tumors

李懿 博士, 总裁兼首席科学官, 广州市香雪生命科学中心 [ Dr. Yi Li, President and Chief Scientific Officer, Guangdong Xiangxue Life Sciences ]

主旨演讲:Progress on TCR-T Development and Solid Tumor Treatment
-- Recent progress on TCR-T product development
-- Clinical practice on TCR-T treating solid tumors

朱逸 博士,亚太地区商务负责人, T-Cure Bioscience [ Dr. Yi Zhu, Head of Business Development Asia Pacific and COO, T-Cure Bioscience ]

主旨演讲:Surface Density of CAR Molecules Modulate the Kinetics of CAR-T Cells In Vivo
李建强 博士, 创始人兼首席科学官, 河北森朗生物 [ Dr. Jianqiang Li, Founder and Chief Scientific Officer, Hebei Senlang Biotech ]

主旨演讲:Development Next-generation off-the-shelf CAR-T cell therapy
曹卫  博士, 董事长, 总裁兼首席执行官, 亘喜生物 [ Dr. William Cao, President and Chief Executive Officer, Gracell Biotechnology ]

主旨演讲:The Research and Proceedings of CAR-T for Treating the AML
张继帅 博士, 首席科学官, 深圳普瑞金生物 [ Dr. Jishuai Zhang, Chief Scientific Officer, The Pregene Biopharma Company ]

主旨演讲:Cell Therapy Manufacturing Commercialization -- Strategy and Challenges

Harry Lam 博士, 执行副总裁, 技术运营, 上海药明巨诺生物科技有限公司 [ Dr. Harry Lam, Executive Vice President of Technical Operations, JW Therapeutics ]

主旨演讲: 利用流式细胞术 CAR-T 细胞的鉴定与研究
Flow cytometry can be helpful in CAR-T design and tocicity prediction

Identify the quality of immune cells

MRD detection after CAR-T

Immune surveillance

Cytokines by ELISA, detect more cytokines by FCM
王慧 博士, 临床诊断部 副主任, 流式细胞实验室 主任, 陆道培疫疗集团
[Dr. Hui Wang, Deputy Director, Clinical Diagnostic Dept, Director, Flow Cytometry Lab, Lu Daopei Medical Group; CEO & CMO, Synarc Research Laboratory (Beijing) Ltd]

* The Interactive Panel Discussion(s):
圆桌讨论: Strengthening Collaboration and Revolution in Future CAR-T Cell Therapy and How Will it Scale over the Next Decades
Panelists:
林欣 教授
基础医学系系主任, 清华大学医学院
Brian Hosung Min 博士
首席执行官, GenScript ProBio
Alvin Luk
博士
首席执行官武汉纽福斯生物科技有限公司
刘必佐 先生
首席执行官 首席财务官, 西比曼生物科技集团
何霆 博士
首席执行官, 北京艺妙神州医药科技有限公司
王立群 博士
首席执行官, 复星凯特生物科技有限公司

小组讨论: Development of Safe and Potent CAR-TCR Cell Therapy in China targeting Hematological Malignancies and Solid Tumor
Panelists:
李华顺 博士
总裁兼首席执行官, 阿思科力
袁纪军 博士

首席执行官,吉凯基因
林彦妮 博士

首席技术官,苏州克睿基因生物科技有限公司
吕璐璐 博士

首席执行官,合源生物

周向军 博士
首席科学官, 恒瑞源正

许中伟 教授
董事长兼首席科学官,贝赛尔特

小组讨论: Establishing a Robust, Scalable, Automated, Functionally-closed Manufacturing Process to Support a Pipeline of Emerging CAR-T Cell Immunotherapy
Overcome the viral vector supply bottleneck for the clinical development timeline

Overcome the equipment capacity limitation for implementing a robust automated & closed processing

How to manufacturing a large batch of allogeneic CAR T drug product with homogeneity and a robust post thaw recovery

Overcome the starting cell source limitation & variation, how to secure an unlimited, identical, clean cells (free of human viruse infection) for allogeneic CAR T product manufacturing
Panelists:
Harry Lam
博士
执行副总裁, 技术运营主管, 上海药明巨诺生物科技有限公司
蒋忻坡 博士
高级总监, 方法分析/工艺验证/QC/QA, 南京传奇生物

何霆 博士
首席执行官, 北京艺妙神州医药科技有限公司
杨林 博士
首席执行官, 博生吉医药科技(苏州)有限公司

俞磊 博士
首席执行官, 上海优卡迪生物医药科技有限公司

精准肿瘤免疫治疗研发 议程和讨论热点:
主旨演讲:Future Cancer Immunotherapy Revolution
-- Immunotherapy Revolution: The discovery and development of immune checkpoint inhibitors has revolutionized the cancer treatment

-- Current Challenges in immunotherapy: biomarker identification, efficacy, and drug resistance

-- Next-Generation Immuno-oncology agents: New approaches to remove obstacles to immune function
秦续科 博士, 首席医学官, 科望医药 [ Dr. Steve Chin, Chief Medical Officer, Elpiscience Biopharma ]


主旨演讲:Advancing siRNA Therapeutics for Enhancing Antitumor Activity of Immune Checkpoint Inhibitor
Abstract: Using a proprietary and optimized polypeptide nanoparticle-based delivery technology, we have developed the novel anti-fibrosis and anti-cancer therapeutics with siRNAs targeting both TGFβ1 and Cox-2 simultaneously (STP705), resulting in human fibroblasts apoptosis. STP705 was initially used for local treatments for skin hypertrophic scar and non-melanoma skin cancer. STP707 (a systemic formulation of STP705) was further advanced for treatment of liver fibrosis and cholangiocarcinoma, both of these indications have received Orphan drug designations by US FDA. Using a mouse syngeneic model of hepatocellular carcinoma, we tested a therapeutic potential of antitumor activity with a combination of STP707 and PD-L1 mAb. After multiple IV administrations twice a week, both single agent of STP707 and the combination treatments resulted in strong antitumor activity, more potent than those treated with Sorafenib and PD-L1 alone. Those antitumor activity were further supported by significant increase of CD8+ and CD4+ T cell infiltrations into the tumor tissue. I will discuss the unique advantage of our Polypeptide Nanoparticle (PNP) technology platform for safe and efficient siRNA delivery, and our strategy for advancing multiple clinical studies ongoing in both USA and China.
陆阳 博士, 总裁兼首席执行官, 圣诺制药 [ Dr. Patrick Y. Lu, President & Chief Executive Officer, Sirnaomics ]

主旨演讲:Small Molecule, Big Impact – Targeting Synthetic lethality for Anticancer Therapy
包骏 博士, 总裁兼首席执行官, 英派药业 [ Dr. Jun Bao, President and Chief Executive Officer, IMPACT Therapeutics ]

主旨演讲:Development and Commercialization of Globally Innovative Medicines in China

-- The benefits and challenges of developing globally innovative medicines in China

-- The benefits and challenges of having multiple global partners

-- What the future will bring to the pharmaceutical industry in China

Kerry Blanchard 博士, 首席执行官, 云顶新耀 [ Dr. Kerry L. Blanchard, Chief Executive Officer, Everest Medicines ]

主旨演讲:Cancer Immunotherapy: Opportunity and Challenge
Abstract: Therapy with immune checkpoint inhibitors has revolutionized cancer therapy. Multiple checkpoint inhibitors, including anti-PD1/PD-L1 or anti-CTLA-4 antibodies, have been approved for patients with advanced cancer. However, all currently approved checkpoint inhibitors when used as single-agent therapy only result in modest clinical improvement in patients with advanced disease. In this presentation, I will discuss the following topics:
• Opportunities and challenges of immune checkpoint inhibitors for cancer treatment
• Basic principles of cancer immune checkpoint inhibitor combination therapies and their potential clinical applications
• Future for cancer immunotherapies

袁瑞荣 博士, 总裁兼首席医学官,  阿诺医药 [ Dr. Ruirong Yuan, President, CMO and Board Director, Adlai Nortye Biopharma ]

主旨演讲:Strategy and Technology Investment for Innovative Medicines
-- Innovative medicines in China: progresses and gaps
-- Lead identification technologies and structure-based drug design
-- Computer-Accelerate Rational Discovery (CARD) and Artificial Intelligence

Xiayang Qiu 博士, 创始人兼首席执行官, 齐鲁锐格 [ Dr. Xiayang Qiu, Founder and Chief Executive Officer, Qilu Regor Therapeutics ]

小组讨论: Panel Discussion: New Modalities Development Opportunities and Challenges
Panelists:
施晨阳 博士, 管理合伙人, 思嘉基金, 创始董事, 百华协会
-- Managing Partner, Serica Capital, Founding Director, BayHelix
Tao Fu 博士, 总裁兼首席运营官, 再鼎医药
-- President and COO, Zai Laboratories
Jonathan Wang
博士, 商务开发高级副总裁, 再鼎医药
-- Senior Vice President, Head of Business Development, Zai Laboratories
Blake Salisbury 博士, 商务开发副总裁, 信达生物
-- Vice President, Business Development, Innovent Biologics

小组讨论: 促进源于中国的创新中国未来癌症免疫肿瘤药品开发及临床研究战略
Panel Discussion: Promoting China Innovation – Revolution in Future Cancer Immunotherapies in China:
Panelists:
李正卿 博士, 全球副总裁, 总经理, 默沙东研发 (中国) 有限公司, 默沙东实验室
-- Vice President and Head of MSD China R&D, Merck Research Laboratories

王莉 博士, 高级副总裁,药物发展和医学事务中心负责人, 礼来中国
-- Senior Vice President and Head of Lilly China Drug Development & Medical Affairs Center (LCDDMAC), Eli Lilly

顾娟红 女士, 副总裁, 研发创新中心总监, 肿瘤治疗与罕见病治疗总监, 法国益普生集团
-- Vice President, Head of R&D Innovation Hub, Therapeutic Area Oncology / Rare Diseases, IPSEN

金建军 博士, 临床开发总监, 诺华 中国
-- Head of Clinical Development, Novartis, China
周辉 博士, 副总裁, 医学科学与战略肿瘤部, 信达生物制药集团
-- Vice President, Medical Science and Strategy Oncology, Innovent Bio
尹鹤群 博士, 首席科学官, 复星医药
-- Chief Scientific Officer, Fosun Pharma

 

查看更多

会议嘉宾

(最终出席嘉宾以会议现场为准)


 APRDL 2020 峰会主席:
** Tsinghua University [ 清华大学 ]

-- 林欣 教授, 基础医学系系主任, 清华大学医学院 ( Professor and Chairman, School of Medicine, Department of Basic Medical Sciences, Tsinghua University )

●  CEO Fireside Chat: 国内CAR-T 商业化与产业化之路
-- 刘必佐 先生, 首席执行官 兼 首席财务官, 西比曼生物科技集团 ( CBMG )
-- 王立群 博士
, 首席执行官, 复星凯特生物科技有限公司 ( Fosun-Kite )
-- 何霆 博士, 首席执行官, 北京艺妙神州医药科技有限公司( ImmunoChina )
-- 杨林 博士, 首席执行官, 博生吉医药科技(苏州)有限公司
( PersonGen BioTherapeutics )
-- 俞磊 博士, 首席执行官, 上海优卡迪生物医药科技有限公司 (UniCAR-Therapy)

●  CAR-T 细胞治疗产品的生产工艺与质量控制
-- Harry Lam 博士, 执行副总裁, 技术运营, 药明巨诺 ( JW Therapeutics )
-- 蒋忻坡 博士, 高级总监, 方法分析/工艺验证/QC/QA, 南京传奇生物 ( Legend Biotech )

● 罕见病AAV基因治疗产品在国内的开发现状
-- 肖溯 博士首席技术官,  武汉纽福斯生物科技有限公司( Neurophth Therapeutics )
-- Alvin Luk 博士,首席执行官,  武汉纽福斯生物科技有限公司( Neurophth Therapeutics )

● 开发新型TCR细胞疗法产品治疗新冠肺炎COVID-19
-- 林欣 教授, 基础医学系系主任, 清华大学医学院 ( Tsinghua University, School of Medicine )
-- 张宇 博士, 高级副总裁兼首席科学官, 中源协和( VCANBIO Cell & Gene Engineering )

● CAR-T/TCR-T/CAR-NK/TIL 细胞治疗产品的临床开发与最新进展
-- 何霆 博士, 首席执行官, 北京艺妙神州医药科技有限公司 ( ImmunoChina ) ( CD-19 CAR-T )
-- 李建强 博士, 创始人兼首席科学官, 河北森朗生物 ( Senlang Bio )  [ 双靶点CAR-T(CD19+CD22)]
-- 汪文 博士, 首席医学官, 驯鹿医药 ( IASO Biotherapeutics ) ( BCMA CAR-T )
-- 孙艳 女士, 副总裁, 细胞药物BU总经理, 上海细胞治疗集团 ( Shanghai Cell Therapy Group ) (  Non-Viral CAR-T Cell Therapy )
-- 张同存 教授, 董事长, 武汉波睿达生物科技有限公司, 院长, 武汉科技大学生命科学与健康学院 ( Wuhan Bio-Raid ) ( CD-30 CAR-T )
-- 钱程 教授, 首席科学家, 重庆精准生物技术有限公司 ( Chongqing Precision Biotech ) ( pCAR-19B )
-- 代红久 博士, 首席执行官, 南京凯地生物科技有限公司 ( Nanjing KAEDI Biotech ) ( NKG2D CAR-T Cell Therapy )
-- 李华顺 博士, 总裁兼首席执行官, 阿思科力 ( Asclepius Technology Company Group ) ( CAR-NK )
-- 汪薇 博士, 临床开发副总裁, 科济生物医药(上海)有限公司 ( CARsgen Therapeutics )
-- 袁纪军 博士, 首席执行官, 吉凯基因 ( Genbase )
-- 林彦妮 博士
, 首席技术官, 苏州克睿基因生物科技有限公司 ( Cure Genetics )

-- 王恩秀 博士, 首席执行官, 南京卡提医学科技有限公司 ( Nanjing CART-MED )
-- 王明军 教授, 执行院长, 深圳市因诺转化医学研究院 (  Shenzhen Institute for Innovation and Translational Medicine )

-- 吕璐璐 博士, 首席执行官, 合源生物 ( Juventas Cell Therapy )
-- 李懿 博士
, 总裁兼首席科学官, 广州市香雪生命科学中心 ( Guangdong Xiangxue Life Sciences )
-- 曹卫 博士
, 董事长, 总裁兼首席执行官, 亘喜生物 ( Gracell Biotechnology )
-- 张继帅 博士
, 首席科学官, 深圳普瑞金生物 ( The Pregene Biopharma Company )
-- 许中伟 博士,
董事长兼首席科学官, 贝赛尔特 ( Bioceltech Therapeutics )

-- 周向军 博士, 首席科学官, 恒瑞源正 ( HRYZ BIO TECH )
-- 朱逸 博士, 亚太地区商务负责人, T-Cure Bioscience
--
林欣 教授, 基础医学系系主任, 清华大学医学院,创始人, 华夏英泰 ( China Immunotech )


●  Precision Cancer Immunotherapy Revolution : 精准免疫肿瘤生物新药研发
-- 李正卿 博士, 全球副总裁, 中国研发中心总裁, 默沙东研发 (中国) 有限公司, 默沙东实验室 (MSD)
-- 王莉 博士
, 高级副总裁, 药物发展和医学事务中心负责人, 礼来制药 ( Eli Lilly )
-- 顾娟红 女士,
副总裁, 研发创新中心总监, 肿瘤治疗与罕见病治疗总监, 法国益普生集团 ( IPSEN )
-- 金建军 博士
, 中国开发总监, 诺华制药 ( Novartis )
-- 周辉 博士
, 副总裁, 医学科学与战略肿瘤部, 信达生物制药集团 ( Innovent Bio )
-- 尹鹤群 博士
, 首席科学官, 复星医药 ( Fosun Pharma )
-- 秦续科 博士, 首席医学官, 科望医药 ( Elpiscience Biopharma )
-- 郭晓宁 博士
, 研发负责人兼首席医学官, 赛生医药 ( SciClone Pharmaceuticals )
-- 陆阳 博士
, 总裁兼首席执行官, 圣诺制药 ( Sirnaomics )
( SiRNA Therapeutics )
-- 包骏 博士, 总裁兼首席执行官, 英派药业 ( IMPACT Therapeutics ) ( Synthetic lethality Anticancer Therapy )
-- Kerry Blanchard 博士, 首席执行官, 云顶新耀  ( Everest Medicines )
-- Tao Fu 博士, 总裁兼首席运营官, 再鼎医药 ( Zai Laboratory )

-- Jonathan Wang 博士, 商务开发高级副总裁, 再鼎医药 ( Zai Laboratory )
-- Blake Salisbury 博士
, 商务开发副总裁, 信达生物 ( Innovent Biologics )

-- Xiayang Qiu 博士, 创始人兼首席执行官, 齐鲁锐格 ( Qilu Regor Therapeutics )
-- 施晨阳 博士
, 管理合伙人, 思嘉基金, 创始董事, 百华协会(BayHelix)
etc.,


● 80+ 国内外知名演讲嘉宾 & 500+ 专业高层参会代表
● 70%+核心市场(主要为 来源于中国及全球的生物医药公司、医院、学术机构)参会者
● 60%+公司决策层及总监级别以上参会者
● 3天高层峰会+定制化且提前预留安排的一对一交流会议+8小时的合作交流及茶歇午宴+1场鸡尾酒晚宴


查看更多

参会指南

会议门票 场馆介绍


票种名称 价格 原价 票价说明
药企(Pharma/Biotech) ¥4800 ¥4800 团体票买三赠一
非药企(Service / Solution Providers) ¥6800 ¥6800 团体票买三赠一

查看更多

上海浦东汤臣洲际大酒店

坐落于陆家嘴金融贸易中心的上海锦江汤臣洲际大酒店地理位置优越便捷,5分钟步行即达城市轨道交通枢纽--世纪大道地铁站,可换成2,4,6,9号线。 步行3分钟可达多个商场及餐饮综合区。我们专业的服务团队为您提供独具匠心且纯正的当地美味及全球美食。辅以位于顶楼的洲际行政俱乐部一览城市美景,修葺一新的洲际俱乐部客房以及提供个性化服务的洲际俱乐部团队,定会为您的商务或休闲出行营造豪华且温馨的家外之家入住体验。

温馨提示
酒店与住宿: 为防止极端情况下活动延期或取消,建议“异地客户”与活动家客服确认参会信息后,再安排出行与住宿。
退款规则: 活动各项资源需提前采购,购票后不支持退款,可以换人参加。

活动家为本会议官方合作
报名平台,您可在线购票

会议支持:

  • 会员折扣
    该会议支持会员折扣
    具体折扣标准请参见plus会员页面
  • 会员返积分
    每消费1元累积1个会员积分。
    仅PC站支持。
  • 会员积分抵现
    根据会员等级的不同,每抵用1元可使用的积分也不一样,具体可参见PLUS会员页面。 仅PC站支持。

会议地点 查看大图

部分参会单位

主办方没有公开参会单位

邮件提醒通知

分享到微信 ×

打开微信,点击底部的“发现”,
使用“扫一扫”即可将网页分享至朋友圈。

录入信息

请录入信息,方便生成邀请函